Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Late Effects of Radiation Prime the Brain Microenvironment for Accelerated Tumor Growth.

Duan C, Yang R, Yuan L, Engelbach JA, Tsien CI, Rich KM, Dahiya SM, Johanns TM, Ackerman JJH, Garbow JR.

Int J Radiat Oncol Biol Phys. 2018 Aug 29. pii: S0360-3016(18)33639-3. doi: 10.1016/j.ijrobp.2018.08.033. [Epub ahead of print]

PMID:
30171879
2.

Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.

Gabani P, Fischer-Valuck BW, Johanns TM, Hernandez-Aya LF, Keller JW, Rich KM, Kim AH, Dunn GP, Robinson CG, Chicoine MR, Huang J, Abraham CD.

Radiother Oncol. 2018 Aug;128(2):266-273. doi: 10.1016/j.radonc.2018.06.017. Epub 2018 Jun 27.

PMID:
29960685
3.

BRAF-Targeted Therapy in the Treatment of BRAF-Mutant High-Grade Gliomas in Adults.

Johanns TM, Ansstas G, Dahiya S.

J Natl Compr Canc Netw. 2018 Apr;16(4):451-454. doi: 10.6004/jnccn.2018.7029. No abstract available.

PMID:
29632063
4.

Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy.

Gabani P, Robinson CG, Ansstas G, Johanns TM, Huang J.

Radiother Oncol. 2018 May;127(2):310-317. doi: 10.1016/j.radonc.2018.02.022. Epub 2018 Mar 11.

PMID:
29534829
5.

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.

Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson C, Hansen LJ, Johanns TM, Sanchez-Perez L, Chandramohan V, Yu YA, Bigner DD, Giles A, Healy P, Dranoff G, Weinhold KJ, Dunn GP, Fecci PE.

Clin Cancer Res. 2018 Sep 1;24(17):4175-4186. doi: 10.1158/1078-0432.CCR-17-1846. Epub 2018 Feb 7.

PMID:
29437767
6.

Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma.

Johanns TM, Ferguson CJ, Grierson PM, Dahiya S, Ansstas G.

J Natl Compr Canc Netw. 2018 Jan;16(1):4-10. doi: 10.6004/jnccn.2017.7032.

PMID:
29295876
7.

Management of intracranial melanomas in the era of precision medicine.

Young GJ, Bi WL, Wu WW, Johanns TM, Dunn GP, Dunn IF.

Oncotarget. 2017 Jul 13;8(51):89326-89347. doi: 10.18632/oncotarget.19223. eCollection 2017 Oct 24. Review.

8.

Comprehensive Analysis of Hypermutation in Human Cancer.

Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A.

Cell. 2017 Nov 16;171(5):1042-1056.e10. doi: 10.1016/j.cell.2017.09.048. Epub 2017 Oct 19.

9.

Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications.

Johanns TM, Bowman-Kirigin JA, Liu C, Dunn GP.

Neurosurgery. 2017 Sep 1;64(CN_suppl_1):165-176. doi: 10.1093/neuros/nyx321. No abstract available.

PMID:
28899059
10.

Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma.

Johanns TM, Dunn GP.

Cancer J. 2017 Mar/Apr;23(2):125-130. doi: 10.1097/PPO.0000000000000247. Review.

11.

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.

Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, Uppaluri R, Ferguson C, Schmidt RE, Dahiya S, Ansstas G, Mardis ER, Dunn GP.

Cancer Discov. 2016 Nov;6(11):1230-1236. Epub 2016 Sep 28.

12.

Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.

Johanns TM, Ward JP, Miller CA, Wilson C, Kobayashi DK, Bender D, Fu Y, Alexandrov A, Mardis ER, Artyomov MN, Schreiber RD, Dunn GP.

Cancer Immunol Res. 2016 Dec;4(12):1007-1015. Epub 2016 Oct 31.

13.

High incidence of TERT mutation in brain tumor cell lines.

Johanns TM, Fu Y, Kobayashi DK, Mei Y, Dunn IF, Mao DD, Kim AH, Dunn GP.

Brain Tumor Pathol. 2016 Jul;33(3):222-7. doi: 10.1007/s10014-016-0257-5. Epub 2016 Mar 9.

14.

Selective culling of high avidity antigen-specific CD4+ T cells after virulent Salmonella infection.

Ertelt JM, Johanns TM, Mysz MA, Nanton MR, Rowe JH, Aguilera MN, Way SS.

Immunology. 2011 Dec;134(4):487-97. doi: 10.1111/j.1365-2567.2011.03510.x.

15.

Early eradication of persistent Salmonella infection primes antibody-mediated protective immunity to recurrent infection.

Johanns TM, Law CY, Kalekar LA, O'Donnell H, Ertelt JM, Rowe JH, Way SS.

Microbes Infect. 2011 Apr;13(4):322-30. doi: 10.1016/j.micinf.2010.11.004. Epub 2010 Dec 4.

16.

Regulatory T cell suppressive potency dictates the balance between bacterial proliferation and clearance during persistent Salmonella infection.

Johanns TM, Ertelt JM, Rowe JH, Way SS.

PLoS Pathog. 2010 Aug 12;6(8):e1001043. doi: 10.1371/journal.ppat.1001043.

17.

Interleukin (IL)-21-independent pathogen-specific CD8+ T-cell expansion, and IL-21-dependent suppression of CD4+ T-cell IL-17 production.

Ertelt JM, Johanns TM, Rowe JH, Way SS.

Immunology. 2010 Oct;131(2):183-91. doi: 10.1111/j.1365-2567.2010.03287.x.

18.

Naturally occurring altered peptide ligands control Salmonella-specific CD4+ T cell proliferation, IFN-gamma production, and protective potency.

Johanns TM, Ertelt JM, Lai JC, Rowe JH, Avant RA, Way SS.

J Immunol. 2010 Jan 15;184(2):869-76. doi: 10.4049/jimmunol.0901804. Epub 2009 Dec 21.

19.

Selective priming and expansion of antigen-specific Foxp3- CD4+ T cells during Listeria monocytogenes infection.

Ertelt JM, Rowe JH, Johanns TM, Lai JC, McLachlan JB, Way SS.

J Immunol. 2009 Mar 1;182(5):3032-8. doi: 10.4049/jimmunol.0803402.

20.

Cytotoxic T-lymphocyte antigen 4 blockade augments the T-cell response primed by attenuated Listeria monocytogenes resulting in more rapid clearance of virulent bacterial challenge.

Rowe JH, Johanns TM, Ertelt JM, Lai JC, Way SS.

Immunology. 2009 Sep;128(1 Suppl):e471-8. doi: 10.1111/j.1365-2567.2008.03001.x. Epub 2008 Dec 17.

21.
22.

Glutamate-induced protease-mediated loss of plasma membrane Ca2+ pump activity in rat hippocampal neurons.

Pottorf WJ 2nd, Johanns TM, Derrington SM, Strehler EE, Enyedi A, Thayer SA.

J Neurochem. 2006 Sep;98(5):1646-56.

23.

Activation of protein kinase C in sensory neurons accelerates Ca2+ uptake into the endoplasmic reticulum.

Usachev YM, Marsh AJ, Johanns TM, Lemke MM, Thayer SA.

J Neurosci. 2006 Jan 4;26(1):311-8.

24.

Restricted STAT5 activation dictates appropriate thymic B versus T cell lineage commitment.

Goetz CA, Harmon IR, O'Neil JJ, Burchill MA, Johanns TM, Farrar MA.

J Immunol. 2005 Jun 15;174(12):7753-63.

Supplemental Content

Loading ...
Support Center